The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.
Official Title: A Non-interventional Study of Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Chinese Prostate Cancer Patients.
Study ID: NCT01123434
Brief Summary: The primary objective is to assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.The secondary objective is to assess the quality of life(QoL)of the high risk localised or locally advanced Chinese prostate cancer patients with immediate postoperative adjuvant hormonal treatment and get the information of immediate postoperative adjuvant hormonal treatment (including the regimen, dosage and duration).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Research Site, Beijing, Beijing, China
Research Site, Guangzhou, Guangdong, China
Research Site, Wuhan, Hubei, China
Research Site, Nanjing, Jiangsu, China
Research Site, Shenyang, Liaoning, China
Research Site, Xi'an, Shanxi, China
Research Site, Chen Du, Sichuan, China
Research Site, Hangzhou, Zhejiang, China
Research Site, Shanghai, , China
Research Site, Tianjin, , China
Name: Karen Atkin
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Yanjing Zhang
Affiliation: AstraZeneca
Role: STUDY_CHAIR
Name: Prof. Na
Affiliation: Peking University Shougang Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Prof. Ye
Affiliation: Tong Ji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR